Table 2.
Diagnostic performance of liver fibrosis biomarkers for predicting advanced liver fibrosis in the whole population (n = 280).
| Cut-Offs | SE | SP | PPV | NPV | ACC | LR+ | LR− | AUROC (95% CI) |
|
|---|---|---|---|---|---|---|---|---|---|
| AAR | ≥0.8 | 26.3 | 84.3 | 20.8 | 87.9 | 76.4 | 1.68 | 0.87 | 0.60 (0.51–0.70) |
| >1 | 13.2 | 93.8 | 25.0 | 87.3 | 82.9 | 2.12 | 0.93 | ||
| APRI | >0.5 | 94.7 | 49.2 | 22.6 | 98.4 | 55.4 | 1.86 | 0.11 | 0.84 (0.78–0.90) |
| >1 | 63.2 | 87.2 | 43.6 | 93.8 | 83.9 | 4.93 | 0.42 | ||
| >1.5 | 36.8 | 93.8 | 48.3 | 90.4 | 86.1 | 5.94 | 0.67 | ||
| FIB-4 | ≥1.45 | 81.6 | 74.4 | 33.3 | 96.3 | 75.4 | 3.18 | 0.25 | 0.88 (0.83–0.93) |
| >3.25 | 36.8 | 96.7 | 63.6 | 90.7 | 88.6 | 11.15 | 0.65 | ||
| Forns | ≥4.2 | 97.4 | 43.8 | 21.4 | 99.1 | 51.1 | 1.73 | 0.06 | 0.90 (0.84–0.95) |
| >6.9 | 40.6 | 95.7 | 75.7 | 83.1 | 82.1 | 9.51 | 0.62 |
Advanced fibrosis was defined as histologic liver fibrosis ≥ F4 according to Ishak et al. [29] for viral chronic liver disease, and ≥F3 according to Brunt/Kleiner et al. for NAFLD [27,28]. AAR, AST to ALT ratio; ACC, accuracy; ALT, alanine aminotransferase; APRI, AST to Platelet Ratio Index; AST, aspartate aminotransferase; AUROC, area under the receiver operating characteristics; BLF, biomarkers of liver fibrosis; Fib-4, fibrosis 4; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; SE, sensitivity; SP, specificity.